The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TROP2 overexpression as predictor of outcome in patients with early triple-negative breast cancer. Exploratory analysis from the GEICAM_CIBOMA trial.
 
Federico Rojo Todo
Honoraria - Abbvie; AstraZeneca; BMS GmbH & Co. KG; GlaxoSmithKline; Lilly; Menarini; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Agilent; Bristol-Myers Squibb; Genomic Health; Guardant Health; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Pfizer; Roche/Genentech; Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Sara Lopez-Tarruella Cobo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Travel, Accommodations, Expenses - AstraZeneca Spain; Gilead Sciences; Pfizer; Roche
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Laura Torrecillas Torres
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; Takeda
Speakers' Bureau - LILLY; MERCK; MSD; NOVARTIS
 
Manuel Ruiz
No Relationships to Disclose
 
Jose Bines
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Knight Pharmaceuticals; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Roche
 
Jose Segalla
No Relationships to Disclose
 
Jose García-Sáenz
Consulting or Advisory Role - AstraZeneca Spain; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; Novartis; Seagen
Speakers' Bureau - AstraZeneca; Lilly; Novartis
Travel, Accommodations, Expenses - Novartis; Roche
 
Roberto Torres
No Relationships to Disclose
 
Juan De La Haba
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Francisco Ayala
Honoraria - Gilead Sciences; Lilly; Novartis; Pfizer; Seagen
Consulting or Advisory Role - Novartis; Seagen
Research Funding - Daichii/Sankyo
Travel, Accommodations, Expenses - Daichii/Sankyo; Gilead Sciences; Novartis; Roche; Roche
 
Henry Gomez
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche; Tecnofarma
Research Funding - AstraZeneca (Inst); MSD Oncology; Novartis (Inst); Roche (Inst)
 
Antonio Llombart-Cussac
Honoraria - AstraZeneca Spain; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Agendia; AstraZeneca Spain; Gilead Sciences; Guardant Health; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Gilead Sciences
Research Funding - Novartis (Inst); Roche/Genentech (Inst)
Expert Testimony - Menarini
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Pfizer; Roche
 
María Rodríguez de la Borbolla
No Relationships to Disclose
 
Jesús Herranz
No Relationships to Disclose
 
Raul Rincon
No Relationships to Disclose
 
Rosalia Caballero
No Relationships to Disclose
 
Begona Bermejo
Consulting or Advisory Role - AstraZeneca Spain; Lilly; Menarini; Novartis
Speakers' Bureau - Daiichi Sankyo; Genentech; MSD; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer
 
Miguel Martin
Stock and Other Ownership Interests - Pfizer
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - AstraZeneca; Novartis; Roche
 
Angel Guerrero
Consulting or Advisory Role - Exact Sciences; Novartis; Pierre Fabre
Expert Testimony - AstraZeneca; Lilly; Menarini; Novartis; Pfizer; Pierre Fabre
Travel, Accommodations, Expenses - Gilead Sciences; Menarini; Novartis; Roche